Teva began trading ordinary shares on NYSE and closed its ADS program
On September 14, 2026, Teva Pharmaceutical Industries Ltd began trading ordinary shares on the New York Stock Exchange under ticker TEVA, replacing American depositary shares (ADS) on a one-to-one basis
Key points
- The company started trading ordinary shares on NYSE and ended its ADS program, exchanging each ADS for one ordinary share
- Investors now buy and sell ordinary shares directly, rather than depositary units, simplifying ownership and potentially boosting liquidity
- If a change of control occurs, the company must repurchase the notes at 101% of their principal amount, which could increase cash outlays
What happened
The company started trading ordinary shares on NYSE and ended its ADS program, exchanging each ADS for one ordinary share
At the same time, ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same ticker TEVA
Why it matters
Investors now buy and sell ordinary shares directly, rather than depositary units, simplifying ownership and potentially boosting liquidity
Risks and unknowns
If a change of control occurs, the company must repurchase the notes at 101% of their principal amount, which could increase cash outlays
The note agreements limit the ability to create liens, undertake sale-leaseback transactions and merge, consolidate, sell, lease or transfer assets, which may restrict financial flexibility
What to watch
Watch the upcoming insider trading reports – they will show whether company executives continue selling shares
Also monitor whether net proceeds from note issuances are transferred by subsidiaries to parent Teva, which can be seen in financial statements
Original sources
- 8-K filing, September 14, 2026
- 8-K filing, September 16, 2026
- 8-K EX-5.1 filing, September 16, 2026
- 4 filing, September 22, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Teva Pharmaceutical Industries
A notification in your browser or on your phone when we publish about Teva Pharmaceutical Industries. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
